Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BNTC
stocks logo

BNTC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
--
--
-0.228
-31.06%
--
--
-0.240
-0%
--
--
-0.315
-25%
Estimates Revision
The market is revising No Change the revenue expectations for Benitec Biopharma Inc. (BNTC) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -5.25%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-42.91%
In Past 3 Month
Stock Price
Go Down
down Image
-5.25%
In Past 3 Month
Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is 26.60 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is 26.60 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.180
sliders
Low
20.00
Averages
26.60
High
32.00
Current: 13.180
sliders
Low
20.00
Averages
26.60
High
32.00
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$35 -> $32
2025-11-24
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$35 -> $32
2025-11-24
downgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Benitec Biopharma to $32 from $35 and keeps a Buy rating on the shares. The firm cites the completed equity financing for the target cut.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$28 -> $35
2025-11-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$28 -> $35
2025-11-04
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Benitec Biopharma to $35 from $28 and keeps a Buy rating on the shares. The company reported "highly positive" interim data reported from the first six patients to receive BB-301, the analyst tells investors in a research note. The firm says all six patients in the ongoing Phase 1b/2a trial met the formal statistical criteria for positive response in the proprietary oculopharyngeal muscular dystrophy responder analysis. H.C. Wainwright increased BB-301's probability of approval to 45% from 40%.
Citizens JMP
Outperform
maintain
$20 -> $22
2025-11-04
Reason
Citizens JMP
Price Target
$20 -> $22
2025-11-04
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Benitec Biopharma to $22 from $20 and keeps an Outperform rating on the shares. Benitec presented a 100% response rate for the BB-301 Phase 1b/2a study at the low dose and debuted a composite primary endpoint that sets an easily achievable bar for FDA approval, the analyst tells investors in a research note. The firm continues to be encouraged by the efficacy of BB-301 with several measures showing improvements as the patient number grows to six from three.
Oppenheimer
Andreas Argyrides
Outperform
downgrade
$35 -> $29
2025-09-16
Reason
Oppenheimer
Andreas Argyrides
Price Target
$35 -> $29
2025-09-16
downgrade
Outperform
Reason
Oppenheimer analyst Andreas Argyrides lowered the firm's price target on Benitec Biopharma to $29 from $35 and keeps an Outperform rating on the shares. Since the last corporate update in July, Benitec remains on track to present full data from the Phase 1b/2a clinical study of lead candidate BB-301 in OPMD in October including all six patients in Cohort 1. Based on durable and clinically meaningful improvements in dysphagia seen in the twelve-month data from Cohort 1 presented at the 2025 MDA conference in March, Oppenheimer expects to see continued benefit. Importantly, these data help to inform regulatory discussions whereby Benitec could advance to a registrational trial with a limited number of additional patients at the current dose based on precedent set by other rare disease companies. The firm continues to view Benitec's "silence and replace" DNA-directed RNA interference platform as differentiated, disease-modifying approach to treating OPMD.
TD Cowen
initiated
2025-07-07
Reason
TD Cowen
Price Target
2025-07-07
initiated
Reason
TD Cowen initiated coverage of Benitec Biopharma with a Buy rating and no price target. The company's DNA-directed 'silence and replace' platform combines RNAi silencing sequences with replacement genes, the analyst tells investors in a research note. The firm believes Benitec's lead asset BB-301 for oculopharyngeal muscular dystrophy showed "compelling" Phase 1/2 clinical data, with improving subjective and objective dysphagia measures in three patients.
JMP Securities
Silvan Tuerkcan
Buy
Maintains
$18 → $20
2025-04-10
Reason
JMP Securities
Silvan Tuerkcan
Price Target
$18 → $20
2025-04-10
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Benitec Biopharma Inc (BNTC.O) is -10.96, compared to its 5-year average forward P/E of -2.94. For a more detailed relative valuation and DCF analysis to assess Benitec Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.94
Current PE
-10.96
Overvalued PE
0.04
Undervalued PE
-5.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.93
Undervalued EV/EBITDA
-1.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
160.60
Current PS
0.00
Overvalued PS
558.14
Undervalued PS
-236.93
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 599.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

BNTC News & Events

Events Timeline

(ET)
2025-11-14
17:06:55
Benitec Biopharma announces Q1 earnings per share of 22 cents, below consensus estimate of 33 cents.
select
2025-11-06 (ET)
2025-11-06
06:16:26
Benitec Biopharma Prices $100M Share Spot Secondary at $13.50
select
2025-11-05 (ET)
2025-11-05
16:44:42
Benitec Biopharma Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-06Newsfilter
Benitec Biopharma Inc. Reveals Pricing for $100 Million Common Stock Sale

  • Public Offering Announcement: Benitec Biopharma Inc. has priced an underwritten public offering of 5,930,000 shares at $13.50 each, alongside a registered direct offering of 1,481,481 shares with Suvretta Capital, aiming for approximately $100 million in gross proceeds.

  • Use of Proceeds: The funds raised will support the development of Benitec's product candidate programs, working capital, and other general corporate purposes.

  • Underwriters and Agents: Leerink Partners, TD Cowen, and Evercore ISI are managing the public offering and acting as placement agents for the direct offering.

  • Company Overview: Benitec Biopharma focuses on gene therapy and RNA interference technologies to develop treatments for chronic conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).

[object Object]
Preview
4.0
11-05Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Benitec Biopharma and Increases Price Target to $35

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro equips traders with tools and information designed to improve their chances of success in the markets.

[object Object]
Preview
9.0
11-03Yahoo Finance
Benitec Biopharma to Update on Phase 1b/2a Clinical Trial of BB-301 for Oculopharyngeal Muscular Dystrophy

  • Investor Webcast Announcement: Benitec Biopharma Inc. will hold an investor webcast on November 3, 2025, at 8:00 am EST to update on the six patients treated in Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD).

  • Company Overview: Benitec Biopharma is a clinical-stage biotechnology company based in Hayward, California, focused on developing genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform for chronic and life-threatening conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Benitec Biopharma Inc (BNTC) stock price today?

The current price of BNTC is 13.18 USD — it has increased 4.77 % in the last trading day.

arrow icon

What is Benitec Biopharma Inc (BNTC)'s business?

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

arrow icon

What is the price predicton of BNTC Stock?

Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is 26.60 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Benitec Biopharma Inc (BNTC)'s revenue for the last quarter?

Benitec Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Benitec Biopharma Inc (BNTC)'s earnings per share (EPS) for the last quarter?

Benitec Biopharma Inc. EPS for the last quarter amounts to -0.22 USD, decreased -54.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Benitec Biopharma Inc (BNTC)'s fundamentals?

The market is revising No Change the revenue expectations for Benitec Biopharma Inc. (BNTC) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -5.25%.
arrow icon

How many employees does Benitec Biopharma Inc (BNTC). have?

Benitec Biopharma Inc (BNTC) has 19 emplpoyees as of December 05 2025.

arrow icon

What is Benitec Biopharma Inc (BNTC) market cap?

Today BNTC has the market capitalization of 445.63M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free